Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdw324
复制
发表时间：
2016-09-01
影响因子：
50.5
通讯作者：
Arnold, D.
中科院分区：
文献类型：
--
作者：
Valle, J. W.;Borbath, I.;Arnold, D.
胆道癌（BTC）占所有人类癌症的< 1%，占所有原发性肝癌的约10%-15%，主要出现在70年代，男性占少数（男女比例为1.2-1.5:1.0）。它们被细分为肝内胆管癌（iCCA）和肝实质外肝外胆管癌（eCCA），前者起源于肝脏内的胆道树；后者又细分为肝门周围胆管癌（pCCA或Klatskin肿瘤）和远端胆管癌（dCCA）[2]， iCCA发生率为10%-20%，pCCA发生率为50%，eCCA发生率为30%-40%。
Biliary tract cancer (BTC), comprising< 1% of all human cancers and∼ 10%–15% of all primary liver cancers, presents mostly in the seventh decade with a small male predominance (male: female ratio of 1.2–1.5: 1.0)[1]. They are subclassified as intrahepatic cholangiocarcinoma (iCCA), originating from the biliary tree within the liver, and extrahepatic cholangiocarcinoma (eCCA), outside the liver parenchyma; the latter is further subdivided into perihilar cholangiocarcinoma (pCCA or Klatskin tumour) and distal cholangiocarcinoma (dCCA)[2], with a frequency of 10%–20% iCCA, 50% pCCA and 30%–40% eCCA.